Agate Medical Investments

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for patients with central nervous system diseases. The company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Currently, BrainsGate is focused on treating acute ischemic stroke through its innovative ischemic stroke system, which involves a miniature electrode implanted in the roof of the mouth during a minimally invasive procedure. This method is performed under local anesthesia and is comparable to standard dental treatments. The company has conducted several clinical trials, including a pivotal trial with 300 patients that validated the safety and efficacy of its treatment. BrainsGate is also engaged in a multi-national, randomized study known as ImpACT-24b, aimed at further assessing the effectiveness of its approach within a critical 24-hour window following a stroke.

CLEW Medical Ltd. is a company that develops an analytics platform designed for healthcare providers and administrators to predict life-threatening complications in intensive care units (ICUs). Founded in 2014 and based in Netanya, Israel, CLEW Medical utilizes ICU data to deliver predictive clinical analytics that assist hospital management and medical personnel in monitoring patient conditions. The platform generates real-time alerts regarding patient deterioration, facilitating early intervention and enhancing clinical outcomes. By employing advanced predictive models and high-dimensional analytics, CLEW's solution can effectively manage large patient populations while addressing individual treatment needs. The team at CLEW Medical brings extensive experience in supporting healthcare institutions in achieving their objectives through innovative research and technology.

Rapid Medical Ltd. specializes in developing neurovascular interventional medical devices aimed at enhancing endovascular treatments, particularly for ischemic and hemorrhagic stroke. Founded in 2008 and based in Yokne'am Illit, Israel, the company offers innovative products such as the Tigertriever, a revascularization device; DRIVEWIRE, a guidewire designed for complex anatomical navigation; and Comaneci, a controllable device for managing aneurysm necks. Rapid Medical's mission focuses on creating safe, effective, and user-friendly medical devices that fulfill physicians' needs while improving patient care. The company has established a distribution network across multiple countries in Europe and Asia, ensuring broad access to its products.

CLEW Medical Ltd. is a company that develops an analytics platform designed for healthcare providers and administrators to predict life-threatening complications in intensive care units (ICUs). Founded in 2014 and based in Netanya, Israel, CLEW Medical utilizes ICU data to deliver predictive clinical analytics that assist hospital management and medical personnel in monitoring patient conditions. The platform generates real-time alerts regarding patient deterioration, facilitating early intervention and enhancing clinical outcomes. By employing advanced predictive models and high-dimensional analytics, CLEW's solution can effectively manage large patient populations while addressing individual treatment needs. The team at CLEW Medical brings extensive experience in supporting healthcare institutions in achieving their objectives through innovative research and technology.

MST Medical Surgery Technologies Ltd. develops innovative image analysis software aimed at enhancing surgical procedures in the healthcare sector. Founded in 2005 by entrepreneurs Ziv Tamir and Moti Sholev, the company is headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida. MST's flagship product, AutoLap, is a robotic image-guided laparoscope positioning system that utilizes advanced image analysis technology to provide surgeons with real-time control during operations, ensuring an optimal field of view. Additionally, the company offers Surgical Training Analytics (STA), a tool designed to capture and analyze images from actual surgeries performed by trainee surgeons. By leveraging artificial intelligence, machine learning, and data analytics, MST aims to empower and automate the surgical environment, thereby improving outcomes for surgeons, healthcare providers, and patients alike.

DiA Imaging Analysis Ltd. specializes in AI-driven ultrasound analysis technology aimed at enhancing cardiac function diagnostics. Established in 2009 and based in Beersheba, Israel, the company provides a suite of automated tools, including LVivo EF for ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain for assessing myocardial strain. These solutions address common challenges faced by clinicians, such as obtaining optimal images and accurately analyzing them for clinical abnormalities. DiA's products, which can be integrated into any ultrasound device or healthcare IT system, also include LVivo SAX for detecting coronary heart disease and LVivo Mobile for mobile ultrasound analysis. The company holds regulatory clearances for its cardiac toolbox and serves a global user base, reflecting its commitment to making ultrasound analysis smarter and more accessible.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Ornim, Inc. is a biomedical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, Ornim specializes in the development and distribution of non-invasive medical monitoring tools that measure blood flow and oxygen saturation in patients. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology to provide real-time, continuous monitoring of cerebral blood flow and tissue oxygenation. CerOx is notable for being the only device on the market that simultaneously measures both blood flow and oxygen saturation, while c-FLOW focuses solely on cerebral blood flow measurement. These devices are designed to assist physicians in making informed clinical decisions, ultimately improving patient outcomes and reducing healthcare costs. Ornim's technology addresses the limitations of existing monitoring methods, and the company holds numerous patents to protect its innovations.

Peptron, Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the development of peptide-based medicines aimed at treating chronic and life-threatening conditions. Founded in 1997, the company utilizes innovative technologies such as SmartDepot, an ultrasonic spray drying method for creating sustained-release injectable microsphere formulations. Peptron's research and development pipeline includes several key products: Luphere Depot for conditions like prostate cancer and endometriosis; SR-Octreotide (PT201) for acromegaly; and two formulations of SR-Exenatide (PT302 and PT320) targeting type 2 diabetes and neurodegenerative diseases, including Parkinson's and Alzheimer's. By leveraging extensive experience in peptide research and drug delivery, Peptron aims to provide long-term solutions for complex health issues.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

EndoChoice is a medical technology company specializing in the design and commercialization of products and services for gastrointestinal (GI) care. Headquartered in Alpharetta, Georgia, EndoChoice offers a comprehensive range of products, including single-use devices, infection control solutions, diagnostics, and advanced imaging systems. The company's proprietary product portfolio features the Full Spectrum Endoscopy™ System, known as Fuse™, which includes colonoscopes and gastroscopes equipped with multiple imagers. This innovative system enables physicians to achieve a 330-degree field of view, significantly improving the detection of polyps compared to traditional endoscopes. With a direct sales organization serving over 2,000 customers in the United States and partnerships with 34 distributors globally, EndoChoice has established a strong presence in the market. Founded in 2008, the company experienced rapid growth and was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. before its acquisition by Boston Scientific in 2016.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Lumenis Ltd. is a leading developer of energy-based medical systems designed for minimally invasive procedures across three primary segments: Surgical, Ophthalmic, and Aesthetic. The Surgical segment provides laser systems and accessories for urology and ENT applications, serving hospitals and clinics. The Ophthalmic segment focuses on laser systems for retinal treatments and glaucoma, catering to ophthalmic practices and hospital departments. The Aesthetic segment offers advanced laser technology for skin treatments and hair removal, targeting physicians in cosmetic medicine. Additionally, Lumenis supports its products with technical training, maintenance services, and logistical support, ensuring comprehensive service for its clients. The company, founded in 1991 and headquartered in Yokneam, Israel, emphasizes the significance of light in its technologies, reflecting its commitment to enhancing quality of life through innovative solutions.

Navotek Medical develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the oncology field, providing tumor localization and tracking for optimal radiation therapy. Navotek’s solution will allow for safer and more effective treatment, improving the chances of tumor eradication and decreasing the rate of complications. In addition, it will potentially improve the efficiency of the treatment procedure by shortening individual sessions as well as entire treatment courses. This will increase the radiation rooms’ throughput which will translate into increased earnings for the hospital.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for patients with central nervous system diseases. The company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Currently, BrainsGate is focused on treating acute ischemic stroke through its innovative ischemic stroke system, which involves a miniature electrode implanted in the roof of the mouth during a minimally invasive procedure. This method is performed under local anesthesia and is comparable to standard dental treatments. The company has conducted several clinical trials, including a pivotal trial with 300 patients that validated the safety and efficacy of its treatment. BrainsGate is also engaged in a multi-national, randomized study known as ImpACT-24b, aimed at further assessing the effectiveness of its approach within a critical 24-hour window following a stroke.

Iscare specializes in assisted reproduction, complex treatment of obesity, gastroenterology, and treatment of idiopathic intestinal inflammations